Table 1 Demographics and baseline characteristics
Esketamine–propofol (n = 56) | Dexmedetomidine–propofol (n = 55) | |
|---|---|---|
Age, month | 23 (14.5, 37.5) | 31 (19, 48) |
Sex | ||
Male | 31 (55.4%) | 31 (56.4%) |
Female | 25 (44.6%) | 24 (43.6%) |
Weight, kg | 12 (10, 15) | 13.5 (10, 16) |
ASA status | ||
I | 41 (73.2%) | 38 (69.1%) |
II | 15 (26.8%) | 17 (30.9%) |
Baseline measurement | ||
HR, beats/min | 109 ± 9 | 108 ± 8 |
SBP, mmHg | 93 (90, 98) | 92 (89, 95) |
DBP, mmHg | 51 (48, 56) | 52 (48, 56) |
SpO2, % | 99 (98, 99) | 99 (98, 99) |
Mild cough | 5 (8.9%) | 4 (7.3%) |
Diagnostic category | ||
Endocrine | 3 (5.4%) | 7 (12.7%) |
ENT/Ophthalmology | 3 (5.4%) | 4 (7.3%) |
Hematology | 1 (1.8%) | 2 (3.6%) |
Neurology | 6 (10.7%) | 6 (10.9%) |
Neurosurgery | 34 (60.7%) | 27 (49.1%) |
Orthopedics | 3 (5.4%) | 4 (7.3%) |
Others | 6 (10.7%) | 5 (9.1%) |
MRI site | ||
Head | 22 (39.3%) | 27 (49.1%) |
Spine | 26 (46.4%) | 21 (38.2%) |
Trunk | 1 (1.8%) | 3 (5.5%) |
Limbs | 2 (3.6%) | 2 (3.6%) |
Head + spine | 3 (5.4%) | 2 (3.6%) |
Head + trunk | 2 (3.6%) | 0 (0%) |